NR3C1 and prostate cancer: This is supported by the observation that Bromodomain and Extra-Terminal motif (BET) inhibitors can restrict NR3C1 expression in enzalutamide-treated prostate cancer cells (85), and GR’s transcriptional activity is modulated in breast cancer cells by depleting SMARCA4, an ATPase subunit of the SWI/SNF complex (105).